Centessa Pharmaceuticals (CNTA) Stock Forecast & Price Target

CNTA Forecast - Frequently Asked Questions

What is Centessa Pharmaceuticals' forecast for 2026?

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Centessa Pharmaceuticals is $40.70, with a high forecast of $62.00 and a low forecast of $30.00.

Should I buy or sell Centessa Pharmaceuticals stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Centessa Pharmaceuticals in the last twelve months. There is currently 1 sell rating, 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CNTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CNTA, but not buy additional shares or sell existing shares.

Does Centessa Pharmaceuticals's stock price have much upside?

According to analysts, Centessa Pharmaceuticals's stock has a predicted upside of 2.78% based on their 12-month stock forecasts.

Has Centessa Pharmaceuticals been upgraded or downgraded by Wall Street analysts recently?

Over the previous 90 days, Centessa Pharmaceuticals's stock had 9 downgrades and 1 upgrade by analysts.

What analysts cover Centessa Pharmaceuticals?

Centessa Pharmaceuticals has been rated by research analysts at B. Riley Financial, Guggenheim, Leerink Partners, Lifesci Capital, Needham & Company LLC, Stephens, Truist Financial, Weiss Ratings, Wells Fargo & Company, and Wolfe Research in the past 90 days.

Do Wall Street analysts like Centessa Pharmaceuticals more than its competitors?

Analysts like Centessa Pharmaceuticals less than other "medical" companies. The consensus rating score for Centessa Pharmaceuticals is 2.21 while the average consensus rating score for "medical" companies is 2.30. Learn more on how CNTA compares to other companies.